Bupropion hydrobromide not checked
FollowEvery change as it happens, and a Monday email
Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- Aminoketone FDA class
- Tested for
- Major Depressive Disorder
- Main trialPhase 4
- “Double-Blind, Placebo-Controlled, Multicenter Study of Efficacy and Safety”In the company’s words, NCT02129751 on ClinicalTrials.gov
- Other names
- Aplenzin
Other drugs for Major Depressive Disorder
- SeltorexantJohnson & Johnson (Janssen) · Phase 3
- AzetukalnerXenon Pharmaceuticals Inc. · Phase 3
- LumateperoneIntra-Cellular Therapies, Inc. · Phase 3
- CYB003Cybin IRL Limited · Phase 3
- Mitizodone PhosphateSunshine Lake Pharma Co., Ltd. · Phase 2/3
- OsavampatorNeurocrine Biosciences · Phase 3
Coming up1
- Jul 2030Phase 4 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Not yet recruiting | Jul 2030 | Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026